The Role of Hyperthermic Intraperitoneal Chemother

Authors: Ramakrishnan Ayloor Seshadri Olivier Glehen

Publish Date: 2016/02/02

Volume: 7, Issue: 2, Pages: 198-207

PDF Link

Abstract

Peritoneal metastasis either synchronous or metachronous is commonly seen in gastric cancer It is associated with a poor prognosis with a median survival of less than one year The outcomes are not significantly improved by the use of systemic chemotherapy We review the relevant literature on the role of HIPEC in gastric cancer Cytoreductive surgery CRS and hyperthermic intraperitoneal chemotherapy HIPEC has been used in three situations in gastric cancer Besides its role as a definitive treatment in patients with established peritoneal metastasis PM it has been used as a prophylaxis against peritoneal recurrence after curative surgery and also as a palliative treatment in advanced peritoneal metastasis with intractable ascites While prophylactic HIPEC has been shown to reduce peritoneal recurrence and improve survival in many randomised trials palliative HIPEC can reduce the need for frequent paracentesis Although CRS with HIPEC has shown promise in increasing the survival of selected patients with established PM from gastric cancer larger studies are needed before this can be accepted as a standard of care

Keywords: